PMID- 37353913
OWN - NLM
STAT- MEDLINE
DCOM- 20230907
LR  - 20230912
IS  - 1460-2350 (Electronic)
IS  - 0268-1161 (Linking)
VI  - 38
IP  - 9
DP  - 2023 Sep 5
TI  - Comparing the peri-implantation endometrial T-bet/GATA3 ratio between control 
      fertile women and patients with recurrent miscarriage: establishment and 
      application of a reference range.
PG  - 1680-1689
LID - 10.1093/humrep/dead132 [doi]
AB  - STUDY QUESTION: Is the ratio of endometrial T-box expressed in T cell (T-bet) and 
      GATA-binding protein 3 (GATA3) changed in patients with recurrent miscarriage 
      (RM) compared to fertile controls? SUMMARY ANSWER: Our study showed a 
      significantly higher T-bet/GATA3 ratio in patients with RM compared with fertile 
      controls. WHAT IS KNOWN ALREADY: The endometrial T-bet (Th1 lineage-committed 
      transcription factor)/GATA3 (Th2 lineage-committed transcription factor) ratio 
      could represent the Th1/Th2 balance, which is particularly important for healthy 
      pregnancy. However, a reliable reference range for the T-bet/GATA3 ratio during 
      the peri-implantation period has not yet been established for use in clinical 
      practice. STUDY DESIGN, SIZE, DURATION: This was a retrospective study carried 
      out in a private fertility center. The control group included 120 women in 
      couples undergoing IVF treatment for male infertility, who had experienced a 
      live-birth baby following the first IVF cycle. The study group included 93 women 
      diagnosed with RM that experienced at least two consecutive clinically 
      spontaneous miscarriages before gestational week 12. The ratio of T-bet/GATA3 was 
      calculated in the control group and RM group. PARTICIPANTS/MATERIALS, SETTING, 
      METHODS: Endometrium samples were collected at mid-luteal phase of the menstrual 
      cycle prior to IVF treatment or pregnancy. The percentage of T-bet+ and GATA3+ 
      cells in total endometrial cells was analyzed using immunohistochemical staining 
      and quantitative analysis. MAIN RESULTS AND THE ROLE OF CHANCE: Using the 95th 
      percentile to define the upper limits of the endometrial T-bet/GATA3 ratio during 
      the mid-luteal phase, the reference range of control fertile women was </=0.22. 
      Compared with the control group, the RM group exhibited a significantly higher 
      T-bet/GATA3 ratio (P = 0.02), and 19.4% (18/93) women with RM exhibited a 
      T-bet/GATA3 ratio above the reference range in the mid-luteal phase. LIMITATIONS, 
      REASONS FOR CAUTION: All patients were recruited from a single center. The 
      stability and clinical value of the endometrial T-bet/GATA3 ratio require further 
      investigation. WIDER IMPLICATIONS OF THE FINDINGS: The present study suggests 
      that an abnormal endometrial T-bet/GATA3 ratio may be one of the risk factors of 
      RM. Further studies are needed to follow up the pregnancy outcomes in patients 
      with RM with normal and abnormal endometrial T-bet/GATA3 ratio according to the 
      reference range. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by 
      Shenzhen Fundamental Research Program (JCYJ20180228164631121, 
      JCYJ20190813161203606, JCYJ20220530172817039). There are no conflicts of interest 
      to declare. TRIAL REGISTRATION NUMBER: N/A.
CI  - (c) The Author(s) 2023. Published by Oxford University Press on behalf of European 
      Society of Human Reproduction and Embryology. All rights reserved. For 
      permissions, please email: journals.permissions@oup.com.
FAU - Yu, Shuyi
AU  - Yu S
AUID- ORCID: 0000-0001-7536-6099
AD  - Shenzhen Key Laboratory of Reproductive Immunology for Peri-Implantation, 
      Shenzhen Zhongshan Institute for Reproduction and Genetics, Fertility Center, 
      Shenzhen Zhongshan Urology Hospital, Shenzhen, China.
AD  - Shenzhen Jinxin Medical Technology Innovation Center, Co., Ltd., Shenzhen, China.
FAU - Diao, Lianghui
AU  - Diao L
AUID- ORCID: 0000-0002-1159-9261
AD  - Shenzhen Key Laboratory of Reproductive Immunology for Peri-Implantation, 
      Shenzhen Zhongshan Institute for Reproduction and Genetics, Fertility Center, 
      Shenzhen Zhongshan Urology Hospital, Shenzhen, China.
AD  - Shenzhen Jinxin Medical Technology Innovation Center, Co., Ltd., Shenzhen, China.
FAU - Lian, Ruochun
AU  - Lian R
AD  - Shenzhen Key Laboratory of Reproductive Immunology for Peri-Implantation, 
      Shenzhen Zhongshan Institute for Reproduction and Genetics, Fertility Center, 
      Shenzhen Zhongshan Urology Hospital, Shenzhen, China.
FAU - Chen, Cong
AU  - Chen C
AD  - Shenzhen Key Laboratory of Reproductive Immunology for Peri-Implantation, 
      Shenzhen Zhongshan Institute for Reproduction and Genetics, Fertility Center, 
      Shenzhen Zhongshan Urology Hospital, Shenzhen, China.
FAU - Huang, Chunyu
AU  - Huang C
AD  - Shenzhen Key Laboratory of Reproductive Immunology for Peri-Implantation, 
      Shenzhen Zhongshan Institute for Reproduction and Genetics, Fertility Center, 
      Shenzhen Zhongshan Urology Hospital, Shenzhen, China.
AD  - Shenzhen Jinxin Medical Technology Innovation Center, Co., Ltd., Shenzhen, China.
FAU - Li, Xinyuan
AU  - Li X
AD  - Shenzhen Key Laboratory of Reproductive Immunology for Peri-Implantation, 
      Shenzhen Zhongshan Institute for Reproduction and Genetics, Fertility Center, 
      Shenzhen Zhongshan Urology Hospital, Shenzhen, China.
AD  - Shenzhen Jinxin Medical Technology Innovation Center, Co., Ltd., Shenzhen, China.
FAU - Li, Yuye
AU  - Li Y
AUID- ORCID: 0009-0008-3328-5002
AD  - Shenzhen Key Laboratory of Reproductive Immunology for Peri-Implantation, 
      Shenzhen Zhongshan Institute for Reproduction and Genetics, Fertility Center, 
      Shenzhen Zhongshan Urology Hospital, Shenzhen, China.
AD  - Shenzhen Jinxin Medical Technology Innovation Center, Co., Ltd., Shenzhen, China.
FAU - Zeng, Yong
AU  - Zeng Y
AUID- ORCID: 0000-0002-6264-283X
AD  - Shenzhen Key Laboratory of Reproductive Immunology for Peri-Implantation, 
      Shenzhen Zhongshan Institute for Reproduction and Genetics, Fertility Center, 
      Shenzhen Zhongshan Urology Hospital, Shenzhen, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
RN  - 0 (GATA3 protein, human)
RN  - 0 (GATA3 Transcription Factor)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Female
MH  - Humans
MH  - Male
MH  - Pregnancy
MH  - *Abortion, Habitual/etiology
MH  - Endometrium/metabolism
MH  - GATA3 Transcription Factor/metabolism
MH  - Reference Values
MH  - Retrospective Studies
MH  - Transcription Factors/metabolism
OTO - NOTNLM
OT  - GATA-binding protein 3
OT  - GATA3
OT  - T-bet
OT  - T-box expressed in T cell
OT  - endometrium
OT  - fertile women
OT  - recurrent miscarriage
OT  - reference range
EDAT- 2023/06/24 11:42
MHDA- 2023/09/06 06:42
CRDT- 2023/06/24 01:13
PHST- 2022/08/25 00:00 [received]
PHST- 2023/04/29 00:00 [revised]
PHST- 2023/09/06 06:42 [medline]
PHST- 2023/06/24 11:42 [pubmed]
PHST- 2023/06/24 01:13 [entrez]
AID - 7206371 [pii]
AID - 10.1093/humrep/dead132 [doi]
PST - ppublish
SO  - Hum Reprod. 2023 Sep 5;38(9):1680-1689. doi: 10.1093/humrep/dead132.